These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38776028)

  • 1. Serum cytokines and creatinine/cystatin C ratio as prognostic biomarkers in advanced cancer patients treated with anti-PD-1/PD-L1 therapy.
    Jin SX; Liu BN; Ji HJ; Wu JR; Li BL; Gao XL; Li N; Zheng ZD; Du C
    Support Care Cancer; 2024 May; 32(6):370. PubMed ID: 38776028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A critical review: serum cytokines and creatinine/cystatin C ratio as prognostic biomarkers in advanced cancer patients treated with anti-PD-1/PD-L1 therapy.
    Uyar GC; Çakmak Öksüzoğlu ÖB; Sütcüoğlu O
    Support Care Cancer; 2024 Jul; 32(8):543. PubMed ID: 39046559
    [No Abstract]   [Full Text] [Related]  

  • 3. Creatinine-to-cystatin C ratio and body composition predict response to PD-1 inhibitors-based combination treatment in metastatic gastric cancer.
    Ji H; Liu B; Jin P; Li Y; Cui L; Jin S; Wu J; Shan Y; Zhang Z; Ming J; Zhang L; Du C
    Front Immunol; 2024; 15():1364728. PubMed ID: 38665913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.
    Zhang Z; Yuan F; Chen R; Li Y; Ma J; Yan X; Wang L; Zhang F; Tao H; Guo D; Huang Z; Zhang S; Li X; Zhi X; Ge X; Hu Y; Wang J
    Front Immunol; 2020; 11():1173. PubMed ID: 32587591
    [No Abstract]   [Full Text] [Related]  

  • 5. Prognostic significance of programmed cell death ligand 1 blood markers in non-small cell lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Zhang N; Chang J; Liu P; Tian X; Yu J
    Front Immunol; 2024; 15():1400262. PubMed ID: 38915398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble PD-L1 predicts tumor response and immune-related adverse events in patients with advanced melanoma treated with anti-PD-1 antibodies.
    Oya K; Nakamura Y; Shen LT; Ishizuki S; Matsusaka S; Fujisawa Y
    J Dermatol; 2024 Jun; 51(6):807-815. PubMed ID: 38433350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients.
    Yang Q; Chen M; Gu J; Niu K; Zhao X; Zheng L; Xu Z; Yu Y; Li F; Meng L; Chen Z; Zhuo W; Zhang L; Sun J
    Front Immunol; 2021; 12():665133. PubMed ID: 33936103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment.
    Oh SY; Kim S; Keam B; Kim TM; Kim DW; Heo DS
    Sci Rep; 2021 Oct; 11(1):19712. PubMed ID: 34611279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Nutritional Index Predicts Outcome of PD-L1 Negative and MSS Advanced Cancer Treated with PD-1 Inhibitors.
    Zhang Y; Jin J; Tang M; Li P; Zhou LN; Du YP; Chen MB
    Biomed Res Int; 2022; 2022():6743126. PubMed ID: 35707390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
    Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S
    Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct circulating cytokine/chemokine profiles correlate with clinical benefit of immune checkpoint inhibitor monotherapy and combination therapy in advanced non-small cell lung cancer.
    Hu Y; Li S; Xiao H; Xiong Y; Lu X; Yang X; Luo W; Luo J; Zhang S; Cheng Y; Zhang L; Dai X; Yang Y; Wang D; Li M
    Cancer Med; 2023 Jun; 12(11):12234-12252. PubMed ID: 37062076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma cytokines interleukin-18 and C-X-C motif chemokine ligand 10 are indicative of the anti-programmed cell death protein-1 treatment response in lung cancer patients.
    Wang Y; Chen H; Zhang T; Yang X; Zhong J; Wang Y; Chi Y; Wu M; An T; Li J; Zhao X; Dong Z; Wang Z; Zhao J; Zhuo M; Huang J
    Ann Transl Med; 2021 Jan; 9(1):33. PubMed ID: 33553326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer.
    Zheng L; Hu F; Huang L; Lu J; Yang X; Xu J; Wang S; Shen Y; Zhong R; Chu T; Zhang W; Li Y; Zheng X; Han B; Zhong H; Nie W; Zhang X
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38641349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of circulating biomarkers of immune-checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinoma.
    Chuma M; Uojima H; Toyoda H; Hiraoka A; Arase Y; Atsukawa M; Itokawa N; Okubo T; Tada T; Numata K; Morimoto M; Sugimori M; Nozaki A; Iwasaki S; Yasuda S; Koshiyama Y; Mishima Y; Tsuruya K; Tokoro C; Miura Y; Hidaka H; Kumada T; Kusano C; Kagawa T; Maeda S
    Hepatol Int; 2024 Oct; 18(5):1472-1485. PubMed ID: 38963640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble PD-L1 as a predictive biomarker in lung cancer: a systematic review and meta-analysis.
    Cheng Y; Wang C; Wang Y; Dai L
    Future Oncol; 2022 Jan; 18(2):261-273. PubMed ID: 34874185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral cytokine levels as predictive biomarkers of benefit from immune checkpoint inhibitors in cancer therapy.
    Ji S; Chen H; Yang K; Zhang G; Mao B; Hu Y; Zhang H; Xu J
    Biomed Pharmacother; 2020 Sep; 129():110457. PubMed ID: 32887027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum cytokine analysis in a cohort of advanced non-small cell lung cancer treated with PD-1 inhibitors reveals predictive markers of CXCL12.
    Xu Y; Ding L; Li H; Peng Z; Ding K; Huang Z; Zhou Z; Xie M; Yan J; Feng S; Fan Y
    Front Immunol; 2023; 14():1194123. PubMed ID: 37359565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials.
    Huang Z; Zheng S; Ding S; Wei Y; Chen C; Liu X; Li H; Xia Y
    J Cancer Res Ther; 2021 Jul; 17(3):676-687. PubMed ID: 34269299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating receptor activator of nuclear factor kappa-B ligand (RANKL) levels predict response to immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC).
    Iuliani M; Simonetti S; Cristofani L; Cavaliere S; Cortellini A; Russano M; Vincenzi B; Tonini G; Santini D; Pantano F
    J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38908859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.